PB1762: ponatinib versus imatinib with reduced-intensity chemotherapy in patients with newly diagnosed philadelphia chromosome–positive (ph+) acute lymphoblastic leukemia (all): phallcon study

PB1762: ponatinib versus imatinib with reduced-intensity chemotherapy in patients with newly diagnosed philadelphia chromosome–positive (ph+) acute lymphoblastic leukemia (all): phallcon study

Detalles Bibliográficos
Autores principales: Jabbour, E., Martinelli, G., Vignetti, M., Kantarjian, Hagop M., Gómez Almaguer, David, Minami, Y., Dombret, H., Hennessy, M., Vorog, A., Wang, B., Ribera, J. M.
Formato: Artículo
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
RC Medicina Interna, Psiquiatría, Neurología
Acceso en línea:http://eprints.uanl.mx/23831/1/23831.pdf

Ejemplares similares